Andrew Martin

10PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 24, 2026
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.

|Apr 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Feb 06, 2026
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.

Aslı D Munzur, Cameron Herberts, Edmond M Kwan

|Oct 10, 2025
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials.

Andrew J Martin, Yu Yang Soon, Katrin Marie Sjoquist

|Jun 02, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

Yu Yang Soon, Katrin Sjoquist, Ian C Marschner

|Jun 23, 2021
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.

Prunella Blinman, Andrew Martin, Michael Jefford

Pageof 2

Frequent Collaborators

5 joint publications

Martin Stockler

3 joint publications

Ian D Davis

2 joint publications

Anthony M Joshua

2 joint publications

Scott Williams